PAX1/SOX1 DNA methylation and cervical neoplasia detection: A Taiwanese Gynecologic Oncology Group (TGOG) study

Cancer Medicine

Volumn 3, Issue 4, 2014, Pages 1062-1074

  Lai, Hung Cheng ^a,b,c   Ou, Yu Che ^d,e   Chen, Tze Chien ^f,g   Huang, Huei Jean ^d,e   Cheng, Ya Min ^h,i   Chen, Chi Hau ^j,k   Chu, Tang Yuan ^l   Hsu, Shih Tien ^m,n   Liu, Cheng Bin ^o   Hung, Yao Ching ^n,p   Wen, Kuo Chang ^q   Yu, Mu Hsien ^b   Wang, Kung Liahng ^c,f,r  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^f MACKAY MEMORIAL HOSPITAL   (Taiwan)

^g TATUNG UNIVERSITY   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁱ NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^j NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^k NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^l TZU CHI UNIVERSITY   (Taiwan)

^m TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

ⁿ CHINA MEDICAL UNIVERSITY   (Taiwan)

^o KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^p CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^q TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^r NURSING AND MANAGEMENT COLLEGE   (Taiwan)

more..

Author keywords

Cervical cancer screening; DNA methylation; PAX1; SOX1

Indexed keywords

GENOMIC DNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX1; TRANSCRIPTION FACTOR SOX1; UNCLASSIFIED DRUG; PAIRED BOX TRANSCRIPTION FACTOR; PAX1 TRANSCRIPTION FACTOR; SOX1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ADULT; ANALYTICAL EQUIPMENT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DNA METHYLATION; ETHNIC GROUP; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOLECULAR PROBE; MULTICENTER STUDY; MULTIPLEX POLYMERASE CHAIN REACTION; PAPANICOLAOU TEST; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TAIWAN; TAIWANESE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VALIDATION PROCESS; VIRUS DETECTION; VIRUS LOAD; WART VIRUS; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; CLINICAL TRIAL; GENETICS; MIDDLE AGED; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA METHYLATION; FEMALE; HUMANS; MIDDLE AGED; PAIRED BOX TRANSCRIPTION FACTORS; ROC CURVE; SOXB1 TRANSCRIPTION FACTORS; TAIWAN; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84904107608     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.253     Document Type: Article

References (55)

1. Christopherson, W. M., J. E. Parker, W. M. Mendez, and F. E. Jr Lundin . 1970. Cervix cancer death rates and mass cytologic screening. Cancer 26:808-811.
2. Quinn, M., P. Babb, J. Jones, and Allen E. 1999. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 318:904-908.
3. Pak, S. C., M. Martens, R. Bekkers, A. J. Crandon, R. Land, and J. L. Nicklin, et al. 2007. Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervix. Aust. N. Z. J. Obstet. Gynaecol. 47:504-507.
4. Mahlck, C. G., H. Jonsson, and P. Lenner . 1994. Pap smear screening and changes in cervical cancer mortality in Sweden. Int. J. Gynaecol. Obstet. 44:267-272.
5. Liu, S., R. Semenciw, A. Probert, and Y. Mao . 2001. Cervical cancer in Canada: changing patterns in incidence and mortality. Int. J. Gynecol. Cancer 11:24-31.
6. Etzioni, R., N. Urban, S. Ramsey, M. McIntosh, S. Schwartz, B. Reid, et al. 2003. The case for early detection. Nat. Rev. Cancer 3:243-252.
7. Forouzanfar, M. H., K. J. Foreman, A. M. Delossantos, R. Lozano, A. D. Lopez, C. J. Murray, et al. 2011. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 378:1461-1484.
8. Fahey, M. T., L. Irwig, and P. Macaskill . 1995. Meta-analysis of Pap test accuracy. Am. J. Epidemiol. 141:680-689.
9. Koliopoulos, G., M. Arbyn, P. Martin-Hirsch, M. Kyrgiou, W. Prendiville, and E. Paraskevaidis . 2007. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. Gynecol. Oncol. 104:232-246.
10. Mayrand, M. H., E. Duarte-Franco, I. Rodrigues, S. D. Walter, J. Hanley, A. Ferenczy, et al. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357:1579-1588.
11. Cuzick, J., A. Szarewski, H. Cubie, G. Hulman, H. Kitchener, D. Luesley, et al. 2003. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362:1871-1876.
12. Nanda, K., D. C. McCrory, E. R. Myers, L. A. Bastian, V. Hasselblad, J. D. Hickey, et al. 2000. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 132:810-819.
13. Ronco, G., P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. D. Palma, A. Del Mistro, et al. 2008. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl. Cancer Inst. 100:492-501.
14. Sankaranarayanan, R., B. M. Nene, S. S. Shastri, K. Jayant, R. Muwonge, A. M. Budukh, et al. 2009. HPV screening for cervical cancer in rural India. N. Engl. J. Med. 360:1385-1394.
15. zur Hausen, H. 2001. Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J. Natl. Cancer Inst. 93:252-253.
16. Woodman, C. B., S. I. Collins, and L. S. Young . 2007. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer 7:11-22.
17. Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, et al. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
18. 2005. ACOG Practice Bulletin. Clinical Management Guidelines for Obstetrician-Gynecologists. Number 61, April 2005. Human papillomavirus. Obstet. Gynecol. 105:905-918.
19. Baay, M. F., J. Weyler, and J. B. Vermorken . 2004. The value of human papillomavirus detection in primary cervical cancer screening. Eur. J. Gynaecol. Oncol. 25:665-669.
20. McCaffery, K., J. Waller, S. Forrest, L. Cadman, A. Szarewski, and J. Wardle . 2004. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG 111:1437-1443.
21. Bulkmans, N. W., L. Rozendaal, P. J. Snijders, F. J. Voorhorst, A. J. Boeke, G. R. Zandwijken, et al. 2004. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44, 102 women. Int. J. Cancer 110:94-101.
22. Cuzick, J., C. Clavel, K. U. Petry, C. J. Meijer, H. Hoyer, S. Ratnam, et al. 2006. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119:1095-1101.
23. Ronco, G., P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. Dalla Palma, A. Del Mistro, et al. 2008. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl. Cancer Inst. 100:492-501.
24. Baylin, S. B., and J. E. Ohm . 2006. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer 6:107-116.
25. Esteller, M. 2008. Epigenetics in cancer. N. Engl. J. Med. 358:1148-1159.
26. Baylin, S. B., and P. A. Jones . 2011. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11:726-734.
27. Laird, P. W. 2003. The power and the promise of DNA methylation markers. Nat. Rev. Cancer 3:253-266.
28. Lai, H. C., Y. W. Lin, R. L. Huang, M .T. Chung, H. C. Wang, Y. P. Liao, et al. 2010. Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer 116:4266-4274.
29. Lim, E. H., S. L. Ng, J. L. Li, A. R. Chang, J. Ng, A. Ilancheran, et al. 2010. Cervical dysplasia: assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy. Gynecol. Oncol. 119:225-231.
30. Chao, T. K., F. Y. Ke, Y. P. Liao, H. C. Wang, C. P. Yu, and H. C. Lai . 2011. Triage of cervical cytological diagnoses of atypical squamous cells by DNA methylation of paired boxed gene 1 (PAX1). Diagn. Cytopathol. 41:41-46.
31. Eijsink, J. J., A. Lendvai, V. Deregowski, H. G. Klip, G. Verpooten, L. Dehaspe, et al. 2011. A four gene methylation marker panel as triage test in hr-HPV positive patients. Int. J. Cancer 130:1861-1869.
32. van der Meide, W. F., S. Snellenberg, C. J. Meijer, A. Baalbergen, T. J. Helmerhorst, W. B. van der Sluis, et al. 2011. Promoter methylation analysis of WNT/beta-catenin signaling pathway regulators to detect adenocarcinoma or its precursor lesion of the cervix. Gynecol. Oncol. 123:116-122.
33. Hesselink, A. T., D. A. Heideman, R. D. Steenbergen, V. M. Coupe, R. M. Overmeer, D. Rijkaart, et al. 2011. Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk human papillomavirus DNA-positive women. Clin. Cancer Res. 17:2459-2465.
34. Overmeer, R. M., J. A. Louwers, C. J. Meijer, F. J. van Kemenade, A. T. Hesselink, N. F. Daalmeijer, et al. 2010. Combined CADM1 and MAL promoter methylation analysis to detect (pre-)malignant cervical lesions in high-risk HPV-positive women. Int. J. Cancer 129:2218-2225.
35. Lai, H. C., Y. W. Lin, T. H. M. Huang, P. Yan, R. L. Huang, H. C. Wang, et al. 2008. Identification of novel DNA methylation markers in cervical cancer. Int. J. Cancer 123:161-167.
36. Ogino, S., T. Kawasaki, M. Brahmandam, M. Cantor, G. J. Kirkner, D. Spiegelman, et al. 2006. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J. Mol. Diagn. 8:209-217.
37. Huang, R. L., C. C. Chang, P. H. Su, Y. C. Chen, Y. P. Liao, H. C. Wang, et al. 2012. Methylomic analysis identifies frequent DNA methylation of zinc finger protein 582 (ZNF582) in cervical neoplasms. PLoS ONE 7:e41060.
38. Pepe, M. S., R. Etzioni, Z. Feng, J. D. Potter, M. L. Thompson, M. Thornquist, et al. 2001. Phases of biomarker development for early detection of cancer. J. Natl. Cancer Inst. 93:1054-1061.
39. Wentzensen, N., M. E. Sherman, M. Schiffman, and S. S. Wang . 2009. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol. Oncol. 112:293-299.
40. Lai, H. C., Y. W. Lin, T. H. Huang, P. Yan, R. L. Huang, H. C. Wang, et al. 2008. Identification of novel DNA methylation markers in cervical cancer. Int. J. Cancer 123:161-167.
41. Lai, H. C., Y. W. Lin, R. L. Huang, M. T. Chung, H. C. Wang, Y. P. Liao, et al. 2010. Quantitative DNA methylation analysis detects cervical intraepithelial neoplasms type 3 and worse. Cancer 116:4266-4274.
42. Wright, T. C. Jr, L. S. Massad, C. J. Dunton, M. Spitzer, E. J. Wilkinson, and D. Solomon . 2007. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am. J. Obstet. Gynecol. 197:346-355.
43. Berghella, V., L. Pereira, A. Gariepy, and G. Simonazzi . 2004. Prior cone biopsy: prediction of preterm birth by cervical ultrasound. Am. J. Obstet. Gynecol. 191:1393-1397.
44. Sadler, L., A. Saftlas, W. Wang, M. Exeter, J. Whittaker, and L. McCowan L . 2004. Treatment for cervical intraepithelial neoplasia and risk of preterm delivery. JAMA 291:2100-2106.
45. Crane, J. M. 2003. Pregnancy outcome after loop electrosurgical excision procedure: a systematic review. Obstet. Gynecol. 102:1058-1062.
46. Mathevet, P., E. Chemali, M. Roy, and D. Dargent . 2003. Long-term outcome of a randomized study comparing three techniques of conization: cold knife, laser, and LEEP. Eur. J. Obstet. Gynecol. Reprod. Biol. 106:214-218.
47. Stoler, M. H., and M. Schiffman . 2001. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 285:1500-1505.
48. Carreon, J. D., M. E. Sherman, D. Guillen, D. Solomon, R. Herrero, J. Jeronimo, et al. 2007. CIN2 is a much less reproducible less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int. J. Gynecol. Pathol. 26:441-446.
49. Holowaty, P., A. B. Miller, T. Rohan, and T. To . 1999. Natural history of dysplasia of the uterine cervix. J. Natl. Cancer Inst. 91:252-258.
50. Ostor, A. G. 1993. Natural history of cervical intraepithelial neoplasia: a critical review. Int. J. Gynecol. Pathol. 12:186-192.
51. Castle, P. E., M. Schiffman, C. M. Wheeler, and D. Solomon . 2009. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet. Gynecol. 113:18-25.
52. Wright, T. C. Jr, L. S. Massad, C. J. Dunton, M. Spitzer, E. J. Wilkinson, and D. Solomon . 2007. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J. Low. Genit. Tract Dis. 11:201-222.
53. Teschendorff, A. E., U. Menon, A. Gentry-Maharaj, S. J. Ramus, D. J. Weisenberger, H. Shen, et al. 2010. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. 20:440-446.
54. Ohm, J. E., K. M. McGarvey, X. Yu, L. Cheng, K. E. Schuebel, L. Cope, et al. 2007. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet. 39:237-242.
55. Tsao, C. M., M. D. Yan, Y. L. Shih, P. N. Yu, C. C. Kuo, W. C. Lin, et al. 2012. SOX1 functions as a tumor suppressor by antagonizing the WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Hepatology 56:2277-2287.